BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

BofA Securities upgraded Tyra Biosciences, a biotech company focusing on precision medicines. Tyra-300 showed promising preclinical results in hypochondroplasia. BofA raised the stock rating to Buy with a $31 price target ahead of TYRA-300's presentation.